Literature DB >> 7905376

Tolerability of levocabastine eye drops.

M Janssens1, S Blockhuys.   

Abstract

Levocabastine is a very potent histamine H1 antagonist, available for ocular use as eye drops containing 0.5 mg/ml of levocabastine with benzalkonium chloride as a preservative. Local tolerability of the eye drops was evaluated by objective measurements including slit lamp, tonometry, fluorescein and rose Bengal staining, ophthalmoscopy, visual acuity and visual field determinations, as well as subjectively by questioning for adverse experiences. Seven ocular tolerability studies were performed in a total of 71 volunteers and 103 patients with allergic conjunctivitis. Levocabasine was given from twice to four times daily for 1-8 weeks. Two studies were open, three were placebo controlled and in two, levocabastine was compared with terfenadine. No changes of either clinical or statistical significance were observed in the ocular or peri-ocular tissues. Subjectively, local irritation, pain and tearing were virtually absent. Detailed ophthalmological tolerance studies therefore showed levocabastine eye drops to be very well tolerated.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7905376     DOI: 10.1007/bf01206245

Source DB:  PubMed          Journal:  Doc Ophthalmol        ISSN: 0012-4486            Impact factor:   2.379


  3 in total

Review 1.  Levocabastine: an effective topical treatment of allergic rhinoconjunctivitis.

Authors:  M M Janssens; G Vanden Bussche
Journal:  Clin Exp Allergy       Date:  1991-05       Impact factor: 5.018

Review 2.  Levocabastine. A review of its pharmacological properties and therapeutic potential as a topical antihistamine in allergic rhinitis and conjunctivitis.

Authors:  K L Dechant; K L Goa
Journal:  Drugs       Date:  1991-02       Impact factor: 9.546

Review 3.  Efficacy of levocabastine in conjunctival provocation studies.

Authors:  M Janssens
Journal:  Doc Ophthalmol       Date:  1992       Impact factor: 2.379

  3 in total
  2 in total

Review 1.  Therapeutic options in ocular allergic disease.

Authors:  M Hingorani; S Lightman
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546

Review 2.  New trends in the treatment of allergic conjunctivitis.

Authors:  W Parys; S Blockhuys; M Janssens
Journal:  Doc Ophthalmol       Date:  1992       Impact factor: 2.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.